Hospital Sírio Libanês, São Paulo, Brazil.
University Hospital of Montpellier, Montpellier, and Desbret Institute of Epidemiology and Public Health, University of Montpellier, Montpellier, France.
Curr Opin Allergy Clin Immunol. 2021 Apr 1;21(2):168-174. doi: 10.1097/ACI.0000000000000722.
To understand the current global epidemiological data of anaphylaxis and identify potential strategies to improve patients' care and prevention.
Anaphylaxis mortality and morbidity statistics (MMS) may gain new perspectives with the implementation of the International Classification of Diseases (ICD)-11 in the forthcoming years. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk, and support decision-making to facilitate healthcare planning and implementation of public health measures to prevent anaphylaxis.
Anaphylaxis is a complex noncommunicable diseases with adverse impact on health-related quality of life of patients and their carriers and a significant proportion of deaths may be preventable. It requires an integrated holistic plan to improve quality of healthcare and gathering accurate and comparable epidemiological data is key. Morbidity related to anaphylaxis seems to be increasing worldwide whereas mortality of anaphylaxis appears to be low and stable, but this still has great challenges in capturing quality anaphylaxis MMS. Improving the quality of epidemiological data related to anaphylaxis should clarify some areas of uncertainty about risk factors, leading to better targeting of strategies to protect those patients at risk. As knowledge derived from populations is key information for more realistic decision-making, the construction of the new section addressed to anaphylaxis in the ICD-11 will allow the collection of more accurate epidemiological data to support quality management of patients, and better facilitate healthcare planning to implement public health measures to prevent and reduce the morbidity and mortality attributable to these conditions.
了解过敏反应的全球流行病学数据，确定改善患者护理和预防的潜在策略。
随着国际疾病分类第 11 版（ICD-11）在未来几年的实施，过敏反应死亡率和发病率统计数据（MMS）可能会有新的视角。提高与过敏反应相关的流行病学数据质量应能澄清有关危险因素的一些不确定领域，从而更好地确定保护那些处于危险中的患者的策略，并为决策提供支持，以促进医疗保健规划和实施公共卫生措施以预防过敏反应。
过敏反应是一种复杂的非传染性疾病，对患者及其携带者的健康相关生活质量有不良影响，其中相当一部分死亡是可以预防的。需要制定一个综合的整体计划来改善医疗保健质量，而收集准确和可比的流行病学数据是关键。全球范围内过敏反应的发病率似乎在增加，而过敏反应的死亡率似乎较低且稳定，但在捕捉过敏反应 MMS 的质量方面仍存在很大挑战。提高与过敏反应相关的流行病学数据质量应能澄清有关危险因素的一些不确定领域，从而更好地确定保护那些处于危险中的患者的策略。由于从人群中获得的知识是更现实决策的关键信息，因此 ICD-11 中针对过敏反应的新章节的构建将允许收集更准确的流行病学数据，以支持患者的质量管理，并更好地促进医疗保健规划，以实施公共卫生措施，预防和减少这些疾病的发病率和死亡率。
